Heparin

"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Descriptor ID	D006493
MeSH Number(s)	D09.698.373.400
Concept/Terms	Heparin Heparin Unfractionated Heparin Heparin, Unfractionated Heparinic Acid Liquaemin Liquaemin Sodium Heparin Sodium Heparin Heparin, Sodium Heparin Sodium alpha-Heparin alpha-Heparin alpha Heparin

Below are MeSH descriptors whose meaning is more general than "Heparin".

Chemicals and Drugs [D]
Carbohydrates [D09]
Polysaccharides [D09.698]
Glycosaminoglycans [D09.698.373]
Heparin [D09.698.373.400]

Below are MeSH descriptors whose meaning is related to "Heparin".

Below are MeSH descriptors whose meaning is more specific than "Heparin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.

Bar chart showing 90 publications over 28 distinct years, with a maximum of 8 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	2	2
1998	0	1	1
1999	1	0	1
2000	0	1	1
2001	1	1	2
2002	2	4	6
2003	1	1	2
2004	1	1	2
2005	1	4	5
2006	2	2	4
2007	5	0	5
2008	3	2	5
2009	2	1	3
2010	2	3	5
2011	0	3	3
2012	1	2	3
2013	4	0	4
2014	2	2	4
2015	1	2	3
2016	2	1	3
2017	3	2	5
2018	1	1	2
2019	1	1	2
2020	6	2	8
2023	0	1	1
2024	3	1	4
2025	2	1	3
2026	1	0	1

Below are the most recent publications written about "Heparin" by people in Profiles.

Chatterjee S, Girardi NI, Crow J, Wieruszewski PM, Grant MC, Cuker A, Warkentin TE, Mims MP, Arora RC, Martin M, Moon MR, Cangut B, Sultan IS, Parker A, Holler JF, Balsam LB, Engelman DT. 2026 American Association for Thoracic Surgery Expert Consensus Document: Diagnosis and management of heparin-induced thrombocytopenia in patients who undergo cardiac surgery. J Thorac Cardiovasc Surg. 2026 Sep; 172(3):487-509.e3.

View in: PubMed
Treverton J, Arnold DM, Ivanov DG, Ivetic N, Zhang Y, Ali HA, Clare R, Kaltashov IA, Kelton JG, Nazy I. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025 Sep 04; 393(9):879-886.

View in: PubMed
Du Y, Yang Y, Nguyen SN, Kaltashov IA. The Role of Long-Range Non-Specific Electrostatic Interactions in Inhibiting the Pre-Fusion Proteolytic Processing of the SARS-CoV-2 S Glycoprotein by Heparin. Biomolecules. 2025 05 28; 15(6).

View in: PubMed
Stubblefield WB, Helderman R, Strokes N, Greineder CF, Barnes GD, Vinson DR, Westafer LM. Factors in Initial Anticoagulation Choice in Hospitalized Patients With Pulmonary Embolism. JAMA Netw Open. 2025 01 02; 8(1):e2452877.

View in: PubMed
Westafer LM, Presti T, Shieh MS, Pekow PS, Barnes GD, Kapoor A, Lindenauer PK. Trends in Initial Anticoagulation Among US Patients Hospitalized With Acute Pulmonary Embolism 2011-2020. Ann Emerg Med. 2024 11; 84(5):518-529.

View in: PubMed
King RM, Peker A, Epshtein M, Arends JM, Brochu AB, Raskett CM, Slazas KJ, Puri AS, Arthur AS, Fiorella D, Gounis MJ, Anagnostakou V. Active drug-coated flow diverter in a preclinical model of intracranial stenting. J Neurointerv Surg. 2024 Jun 17; 16(7):731-736.

View in: PubMed
Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.

View in: PubMed
Yang Y, Du Y, Ivanov D, Niu C, Clare R, Smith JW, Nazy I, Kaltashov IA. Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4. Commun Biol. 2024 03 11; 7(1):308.

View in: PubMed
Habibi S, Hsieh TC, Khanna S. Perioperative Plasma Exchange and Intravenous Immunoglobulin Use for Refractory Heparin-Induced Thrombocytopenia in a Liver Transplant Recipient. Am J Case Rep. 2023 Dec 30; 24:e941865.

View in: PubMed
Lawlor M, Gupta A, Ranard LS, Madhavan MV, Li J, Eisenberger A, Parikh SA, Sethi SS, Masoumi A. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.

View in: PubMed

People

Explore

Similar Concepts

Top Journals